Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mucinex supplemental NDA approved

This article was originally published in The Tan Sheet

Executive Summary

More than a year after Reckitt Benckiser acquired Adams Respiratory Therapeutics, the firm receives FDA's approval to change the debossing of the modified release layer from "A" to "RB" on its MucinexExtended-Release Bi-Layer tablets, according to an April 3 approval letter for a supplemental new drug application (1"The Tan Sheet" Feb. 4, 2008, In Brief). The FDA also approved changing the tablet shape from round to modified oval and allows for blister packaging. Another April 3 FDA approval letter allows Reckitt to change the debossing of the MR layer of Mucinex DM Extended-Release Bi-Layer tablets from "Adams" to "RB.

You may also be interested in...



Reckitt Benckiser/Adams deal wraps

U.K.-based Reckitt Benckiser completes the acquisition of Adams Respiratory Therapeutics, makers of Mucinex-brand cough/cold products, through a cash tender offer "followed by a short-form merger of its indirect wholly owned subsidiary, Twickenham, with and into Adams," the firm announces Jan. 30. Reckitt announced plans to pay remaining Adams shareholders $60 per share, the same price paid in the tender offer made in December 2007, the firm says (1"The Tan Sheet" Jan. 28, 2008, In Brief)...

ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.

FDA Sets New Restrictions For Authorized N95 Decontamination Systems

After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel